AstraZeneca’s NSCLC Therapy Imfinzi Misses Primary Endpoint in Ph3 Study

AstraZeneca's Imfinzi (durvalumab) concurrently administered with chemoradiotherapy did not achieve a Phase 3 primary endpoint of progression-free survival versus CRT alone for the treatment of patients with unresectable, Stage III non-small cell lung cancer.